The problem
Development and uptake of pediatric formulations of antiretroviral drugs could be slow, leaving children living with HIV in urgent need of better medication.
Download the project evaluation
Our response
This project sought to strengthen and stabilize the market for HIV medicines for children in 27 countries. Activities aimed to build support across the supply chain, focus on fewer but better medicines and achieve a reduction in prices.
The project brought new antiretroviral formulations to the market, created healthy competition among suppliers, expanded eligibility criteria for patients to receive treatment, and developed market intelligence on global demand, key trends, and product landscape for antiretroviral medication. The project also improved national capacity for early infant diagnosis of HIV.
By 2016, ten years after the project started, key pediatric antiretrovirals had seen overall price reductions of up to 80%. Some 480,000 children living with HIV – three out of four children with HIV globally – received treatment and more than two million infants were tested for HIV using diagnostic tests specially adapted to their needs.
